Back to Search Start Over

Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection

Authors :
Innovative Medicines Initiative
European Commission
European Federation of Pharmaceutical Industries and Associations
Ministerio de Economía y Competitividad (España)
Stalin Raj, V.
Okba, Nisreen M. A.
Gutierrez-Alvarez, Francisco J.
Drabek, Dubravka
Dieren, Brenda van
Widagdo, W.
Lamers, Mart M.
Widjaja, Ivy
Fernandez-Delgado, Raúl
Solá Gurpegui, Isabel
Bensaid, Albert
Koopmans, Marion P.
Segalés, Joaquim
Osterhaus, Albert D. M. E.
Bosch, Berend Jan
Enjuanes Sánchez, Luis
Haagmans, Bart L.
Innovative Medicines Initiative
European Commission
European Federation of Pharmaceutical Industries and Associations
Ministerio de Economía y Competitividad (España)
Stalin Raj, V.
Okba, Nisreen M. A.
Gutierrez-Alvarez, Francisco J.
Drabek, Dubravka
Dieren, Brenda van
Widagdo, W.
Lamers, Mart M.
Widjaja, Ivy
Fernandez-Delgado, Raúl
Solá Gurpegui, Isabel
Bensaid, Albert
Koopmans, Marion P.
Segalés, Joaquim
Osterhaus, Albert D. M. E.
Bosch, Berend Jan
Enjuanes Sánchez, Luis
Haagmans, Bart L.
Publication Year :
2018

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) continues to cause outbreaks in humans as a result of spillover events from dromedaries. In contrast to humans, MERS-CoV¿exposed dromedaries develop only very mild infections and exceptionally potent virus-neutralizing antibody responses. These strong antibody responses may be caused by affinity maturation as a result of repeated exposure to the virus or by the fact that dromedaries¿ apart from conventional antibodies¿have relatively unique, heavy chain¿only antibodies (HCAbs).

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1286540261
Document Type :
Electronic Resource